- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Dublin Today
By the People, for the People
Prothena Achieves $50M Milestone Payment from Novo Nordisk
Biotech company reaches clinical development milestone for ongoing collaboration.
Published on Mar. 9, 2026
Got story updates? Submit your updates here. ›
Prothena Corporation, a clinical-stage biotechnology company, has announced the achievement of a $50 million milestone payment from Novo Nordisk related to their ongoing collaboration. The payment is tied to the progress of a joint clinical development program between the two companies.
Why it matters
This milestone payment represents a significant financial boost for Prothena, a relatively small biotech firm, and demonstrates the success of its collaboration with pharmaceutical giant Novo Nordisk. It also highlights the potential of Prothena's pipeline and the value that larger partners see in its clinical programs.
The details
The $50 million payment is tied to the achievement of a pre-specified clinical development milestone as part of the ongoing collaboration between Prothena and Novo Nordisk. The two companies are jointly developing a novel therapy targeting a protein implicated in certain neurological and cardiometabolic diseases.
- Prothena announced the milestone payment on March 9, 2026.
The players
Prothena Corporation
A clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative and cardiometabolic diseases.
Novo Nordisk
A leading global pharmaceutical company specializing in diabetes care and other chronic conditions.
What they’re saying
“We are pleased to have achieved this important milestone in our collaboration with Novo Nordisk, which further validates the potential of our novel therapeutic approach.”
— Gene Kinney, President and CEO of Prothena (Business Wire)
What’s next
Prothena and Novo Nordisk will continue to advance the joint clinical program, with the next milestone potentially being the initiation of a Phase 2 study.
The takeaway
This milestone payment demonstrates the value of Prothena's pipeline and the strength of its partnership with a major pharmaceutical company like Novo Nordisk, positioning the company for further growth and development of its innovative therapies.
